Biotechnology

Pew Charitable Trusts awards $20,000 grants to 16 returning scientists, a targeted effort to bolster biomedical research and retain top talent in the region.

Tiny, unlisted impurities in research chemicals can derail studies and undermine scientific integrity. A new analysis reveals the rigorous standards we should demand.

Caidya's union with Simbec-Orion isn't just another M&A deal. It’s a strategic play to build an end-to-end clinical partner for a complex global market.

A new report reveals a massive strategic shift in obesity care. Pharma giants are pouring billions into FGF21, a new drug class aiming beyond weight loss.

Beyond a simple conference, Tsingke Biotech's recent salon was a strategic play to position itself as the linchpin in China's shift to biotech innovation.

A new FDA pilot program with Japan's Kyowa Kirin aims to slash drug approval times. It's an operational innovation that could fix U.S. supply chains.

Trinity Biotech, a diagnostics firm, is entering the $27B AI cooling market. Can its expertise in high-purity fluids solve the data center thermal crisis?

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.

NurExone's modest C$628k funding isn't a sign of weakness, but a masterclass in biotech survival. It's a strategic play in a cautious market.

The world's only lupus-focused fund is betting on a new model blending VC rigor with patient-led strategy. But can this ambitious structure deliver real progress?

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

With a new U.S. patent, Quoin Pharmaceuticals reinforces its strategy for QRX003, a potential first-ever treatment for devastating Netherton Syndrome.

As demand for its blockbuster drugs soars, Novo Nordisk turns to India's Shantha Biologics in a strategic deal that highlights a global supply chain shift.

Candel Therapeutics is betting its future on a pivotal Phase 3 trial for a novel viral immunotherapy, aiming to succeed where checkpoint inhibitors have failed.

A new milestone in a Parkinson's clinical trial isn't just about the science; it's about building the system to deliver a potential cure to the masses.

Following a $103M funding round, Kinaset Therapeutics adds proven dealmakers to its board, signaling a strategic push for its novel inhaled asthma therapy.

With an $85M insider-led round and a seasoned M&A expert as CEO, Flare Therapeutics sharpens its focus on a novel prostate cancer drug, FX-111.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

Allarity Therapeutics just secured a patent until 2042 for its cancer diagnostic. Is this the key to unlocking personalized treatment or a risky biotech bet?

New data reveals how Genelux’s oncolytic virus reawakens chemotherapy's power, offering a potential lifeline in a notoriously difficult-to-treat cancer.